Kalyan Singh Super Speciality Cancer Institute Signs MoU with Sukarma Global LLP to Advance Clinical Drug Trials

February 26, 2026

Kalyan Singh Super Speciality Cancer Institute (KSSSCI), Lucknow has signed a Memorandum of Understanding (MoU) with Sukarma Global LLP, New Delhi, to promote and expand clinical research activities and conduct clinical new drug trials at the Institute.
Under this collaboration, Sukarma Global LLP will play a vital role in managing and facilitating clinical new drug trials at KSSSCI in accordance with regulatory guidelines. The partnership aims to strengthen the development of the new molecule and its applicability in terms of efficacy & toxicity, dose combination for treatment of various type of cancer.
Through this initiative, eligible cancer patients at KSSSCI will have the opportunity to receive treatment with new investigational drugs under approved clinical trials. This will not only provide early access to advanced therapies but also contribute to the development of evidence-based cancer treatment in the country.
Furthermore, once these new drugs receive approval from the Drug Controller General of India (DCGI) for marketing in India, the wider availability and increased production are expected to make such treatments more affordable and accessible to patients.
The Institute believes that this collaboration marks a significant step towards the development of new drugs for cancer patients, which helpful in reducing the mortality and improving the quality of life.
In this occasion, Prof. M.L.B. Bhatt, Director, KSSSCI, Dr.AyushLohiya, Excutive Registrar, Dr. Varun Vijay, Medical Superintendent and Shri SumitSwarup Saini, Director, Sukarma Global, LLP, new delhi&Dr.Garima Srivastava, SMO, Sukarma Global for present during the MoU exchange ceremony.